{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,8]],"date-time":"2025-10-08T00:16:51Z","timestamp":1759882611589,"version":"build-2065373602"},"reference-count":303,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2025,9,17]],"date-time":"2025-09-17T00:00:00Z","timestamp":1758067200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Journal of Surgical Oncology"],"published-print":{"date-parts":[[2025,10]]},"abstract":"<jats:title>ABSTRACT<\/jats:title><jats:p>Peritoneal malignancy often indicates disruptions in multiple physiological systems resulting from widespread cancer. The heterogenous origin and dynamic nature of peritoneal cancer make it difficult to treat with standard approaches that fit into guidelines. We describe how successful treatment should address the underlying pathology, the systemic response to surgical treatments and target the immune perturbations that facilitate the establishment and propagation of this multifaceted disease.<\/jats:p>","DOI":"10.1002\/jso.70075","type":"journal-article","created":{"date-parts":[[2025,9,17]],"date-time":"2025-09-17T07:59:21Z","timestamp":1758095961000},"page":"789-809","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Peritoneal Immunosurgery: Immunotherapy Augmented Surgery for the Treatment of Peritoneal Cancers"],"prefix":"10.1002","volume":"132","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5023-8242","authenticated-orcid":false,"given":"Ada I.","family":"Ozcan","sequence":"first","affiliation":[{"name":"Center for Cell Gene Therapy, Baylor College of Medicine Texas Children's Hospital, Houston Methodist Hospital Houston TX USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arianexys Aquino","family":"L\u00f3pez","sequence":"additional","affiliation":[{"name":"Center for Cell Gene Therapy, Baylor College of Medicine Texas Children's Hospital, Houston Methodist Hospital Houston TX USA"},{"name":"Department of Pediatrics Texas Children's Hospital Houston TX USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mary K.","family":"McKenna","sequence":"additional","affiliation":[{"name":"Center for Cell Gene Therapy, Baylor College of Medicine Texas Children's Hospital, Houston Methodist Hospital Houston TX USA"},{"name":"Department of Molecular and Cellular Biology Baylor College of Medicine Houston TX USA"},{"name":"Department of Medicine Baylor College of Medicine Houston TX USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Malcolm K.","family":"Brenner","sequence":"additional","affiliation":[{"name":"Center for Cell Gene Therapy, Baylor College of Medicine Texas Children's Hospital, Houston Methodist Hospital Houston TX USA"},{"name":"Department of Medicine Baylor College of Medicine Houston TX USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alastair M.","family":"Thompson","sequence":"additional","affiliation":[{"name":"Department of Surgical Oncology Baylor College of Medicine Houston TX USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2025,9,17]]},"reference":[{"issue":"14","key":"e_1_2_8_2_1","doi-asserted-by":"crossref","DOI":"10.3390\/ijms241411288","article-title":"Folate Receptor Targeted Photodynamic Therapy: A Novel Way to Stimulate Anti\u2010Tumor Immune Response in Intraperitoneal Ovarian Cancer","volume":"24","author":"Baydoun M.","year":"2023","journal-title":"International Journal of Molecular Sciences"},{"issue":"1","key":"e_1_2_8_3_1","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1186\/s40425-018-0398-7","article-title":"Combining Surgery and Immunotherapy: Turning an Immunosuppressive Effect Into a Therapeutic Opportunity","volume":"6","author":"Bakos O.","year":"2018","journal-title":"Journal for Immunotherapy of Cancer"},{"issue":"11","key":"e_1_2_8_4_1","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1038\/s41577-020-0306-5","article-title":"A Guide to Cancer Immunotherapy: From T Cell Basic Science to Clinical Practice","volume":"20","author":"Waldman A. D.","year":"2020","journal-title":"Nature Reviews Immunology"},{"key":"e_1_2_8_5_1","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1038\/nri2744","article-title":"Monoclonal Antibodies: Versatile Platforms for Cancer Immunotherapy","volume":"10","author":"Weiner L. M.","year":"2010","journal-title":"Nature Reviews Immunology"},{"key":"e_1_2_8_6_1","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1038\/s43018-022-00418-6","article-title":"Cancer Vaccines: The Next Immunotherapy Frontier","volume":"3","author":"Lin M. J.","year":"2022","journal-title":"Nature Cancer"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15082383"},{"key":"e_1_2_8_8_1","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-002723","article-title":"Adoptive Cellular Therapy in Solid Tumor Malignancies: Review of the Literature and Challenges Ahead","volume":"9","author":"Kirtane K.","year":"2021","journal-title":"Journal for Immunotherapy of Cancer BMJ Publishing Group"},{"issue":"3","key":"e_1_2_8_9_1","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1038\/s41573-018-0006-z","article-title":"Delivery Technologies for Cancer Immunotherapy","volume":"18","author":"Riley R. S.","year":"2019","journal-title":"Nature Reviews Drug Discovery"},{"key":"e_1_2_8_10_1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ejca.2022.12.008","article-title":"on the Origin of Peritoneal Metastases","volume":"181","author":"Rijken A.","year":"2023","journal-title":"European Journal of Cancer"},{"issue":"11","key":"e_1_2_8_11_1","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1038\/s41571-022-00675-5","article-title":"Advances in the Management of Peritoneal Malignancies","volume":"19","author":"Kepenekian V.","year":"2022","journal-title":"Nature Reviews Clinical Oncology"},{"issue":"1","key":"e_1_2_8_12_1","doi-asserted-by":"crossref","first-page":"60","DOI":"10.3390\/cancers14010060","article-title":"Peritoneal Metastasis: Current Status and Treatment Options","volume":"14","author":"Roth L.","year":"2021","journal-title":"Cancers"},{"issue":"11","key":"e_1_2_8_13_1","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1038\/cgt.2016.49","article-title":"Intraperitoneal Immunotherapy: Historical Perspectives and Modern Therapy","volume":"23","author":"Morano W. F.","year":"2016","journal-title":"Cancer Gene Therapy"},{"issue":"1","key":"e_1_2_8_14_1","first-page":"49","article-title":"The Contemporary Management of Peritoneal Metastasis: A Journey From the Cold Past of Treatment Futility to a Warm Present and a Bright Future","volume":"73","author":"Foster J. M.","year":"2023","journal-title":"CA: A Cancer Journal for Clinicians"},{"issue":"1","key":"e_1_2_8_15_1","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1038\/s41572-021-00326-6","article-title":"Primary and Metastatic Peritoneal Surface Malignancies","volume":"7","author":"Cort\u00e9s\u2010Guiral D.","year":"2021","journal-title":"Nature Reviews Disease Primers"},{"issue":"1","key":"e_1_2_8_16_1","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.tice.2016.11.004","article-title":"The Histophysiology and Pathophysiology of the Peritoneum","volume":"49","author":"Baal J. O. A. M.","year":"2017","journal-title":"Tissue and Cell"},{"key":"e_1_2_8_17_1","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.semcdb.2018.09.007","article-title":"Embryology, Anatomy, Physiology and Pathophysiology of the Peritoneum and the Peritoneal Vasculature","volume":"92","author":"Kastelein A. W.","year":"2019","journal-title":"Seminars in Cell & Developmental Biology"},{"issue":"5","key":"e_1_2_8_18_1","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1159\/000479924","article-title":"The Peritoneum: Health, Disease, and Perspectives Regarding Tissue Engineering and Cell Therapies","volume":"204","author":"Amaral R. J. F. C.","year":"2017","journal-title":"Cells Tissues Organs"},{"issue":"1","key":"e_1_2_8_19_1","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1007\/s10555-012-9351-2","article-title":"Cell\u2013Cell and Cell\u2013Matrix Dynamics in Intraperitoneal Cancer Metastasis","volume":"31","author":"Sodek K. L.","year":"2012","journal-title":"Cancer and Metastasis Reviews"},{"issue":"5","key":"e_1_2_8_20_1","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1007\/s10585-016-9791-0","article-title":"Adhesion Molecules in Peritoneal Dissemination: Function, Prognostic Relevance and Therapeutic Options","volume":"33","author":"Sluiter N.","year":"2016","journal-title":"Clinical & Experimental Metastasis"},{"issue":"20","key":"e_1_2_8_21_1","doi-asserted-by":"crossref","first-page":"5107","DOI":"10.3390\/cancers15205107","article-title":"Regional Immunotherapy for Peritoneal Carcinomatosis in Gastroesophageal Cancer: Emerging Strategies to Re\u2010Condition a Maladaptive Tumor Environment","volume":"15","author":"Lewis C. R.","year":"2023","journal-title":"Cancers"},{"issue":"1","key":"e_1_2_8_22_1","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/S1357-2725(03)00242-5","article-title":"The Mesothelial Cell","volume":"36","author":"Mutsaers S. E.","year":"2004","journal-title":"The International Journal of Biochemistry & Cell Biology"},{"issue":"2","key":"e_1_2_8_23_1","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1038\/s41580-018-0080-4","article-title":"New Insights into the Mechanisms of Epithelial\u2013Mesenchymal Transition and Implications for Cancer","volume":"20","author":"Dongre A.","year":"2019","journal-title":"Nature Reviews Molecular Cell Biology"},{"issue":"2","key":"e_1_2_8_24_1","doi-asserted-by":"crossref","first-page":"458","DOI":"10.3390\/jcm11020458","article-title":"The Development of Peritoneal Metastasis From Gastric Cancer and Rationale of Treatment According to the Mechanism","volume":"11","author":"Yonemura Y.","year":"2022","journal-title":"Journal of Clinical Medicine"},{"issue":"3","key":"e_1_2_8_25_1","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1046\/j.1440-1843.2002.00404.x","article-title":"Mesothelial Cells: Their Structure, Function and Role in Serosal Repair","volume":"7","author":"Mutsaers S. E.","year":"2002","journal-title":"Respirology"},{"issue":"3","key":"e_1_2_8_26_1","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1006\/gyno.1999.5388","article-title":"\u03b21\u2010Integrins Partly Mediate Binding of Ovarian Cancer Cells to Peritoneal Mesothelium in Vitro","volume":"73","author":"Strobel T.","year":"1999","journal-title":"Gynecologic Oncology"},{"issue":"10","key":"e_1_2_8_27_1","doi-asserted-by":"crossref","first-page":"9190","DOI":"10.1074\/jbc.M312372200","article-title":"Binding of Ovarian Cancer Antigen CA125\/MUC16 to Mesothelin Mediates Cell Adhesion","volume":"279","author":"Rump A.","year":"2004","journal-title":"Journal of Biological Chemistry"},{"key":"e_1_2_8_28_1","unstructured":"CD44 and beta1 Integrin Mediate Ovarian Carcinoma Cell Adhesion to Peritoneal Mesothelial Cells."},{"issue":"1","key":"e_1_2_8_29_1","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1023\/A:1026519016213","article-title":"CD44 and \u03b21 Integrins Mediate Ovarian Carcinoma Cell Migration Toward Extracellular Matrix Proteins","volume":"18","author":"Casey R. C.","year":"2000","journal-title":"Clinical & Experimental Metastasis"},{"issue":"5","key":"e_1_2_8_30_1","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1038\/s41571-019-0319-9","article-title":"Harnessing Cancer Immunotherapy During the Unexploited Immediate Perioperative Period","volume":"17","author":"Matzner P.","year":"2020","journal-title":"Nature Reviews Clinical Oncology"},{"issue":"1","key":"e_1_2_8_31_1","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1186\/s12943-017-0742-4","article-title":"Factors Involved in Cancer Metastasis: A Better Understanding to \u201cSeed and Soil\u201d Hypothesis","volume":"16","author":"Liu Q.","year":"2017","journal-title":"Molecular Cancer"},{"issue":"1","key":"e_1_2_8_32_1","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1097\/PAP.0000000000000219","article-title":"Paget's \u201cSeed and Soil\u201d Theory of Cancer Metastasis: An Idea Whose Time Has Come","volume":"26","author":"Akhtar M.","year":"2019","journal-title":"Advances in Anatomic Pathology"},{"key":"e_1_2_8_33_1","doi-asserted-by":"crossref","first-page":"S32","DOI":"10.1016\/j.bbi.2012.03.006","article-title":"Surgery and Stress Promote Cancer Metastasis: New Outlooks on Perioperative Mediating Mechanisms and Immune Involvement","volume":"30","author":"Neeman E.","year":"2013","journal-title":"Brain, Behavior, and Immunity"},{"key":"e_1_2_8_34_1","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1016\/j.semcancer.2022.01.006","article-title":"Surgery\u2010Mediated Tumor\u2010Promoting Effects on the Immune Microenvironment","volume":"86","author":"Cheng X.","year":"2022","journal-title":"Seminars in Cancer Biology"},{"issue":"4","key":"e_1_2_8_35_1","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1038\/nrclinonc.2017.194","article-title":"Perioperative Events Influence Cancer Recurrence Risk After Surgery","volume":"15","author":"Hiller J. G.","year":"2018","journal-title":"Nature Reviews Clinical Oncology"},{"issue":"24","key":"e_1_2_8_36_1","doi-asserted-by":"crossref","first-page":"4869","DOI":"10.1182\/blood-2012-06-438598","article-title":"Platelets Increase the Proliferation of Ovarian Cancer Cells","volume":"120","author":"Cho M. S.","year":"2012","journal-title":"Blood"},{"issue":"1","key":"e_1_2_8_37_1","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1182\/blood-2004-06-2272","article-title":"Platelets and Fibrin(Ogen) Increase Metastatic Potential by Impeding Natural Killer Cell\u2013Mediated Elimination of Tumor Cells","volume":"105","author":"Palumbo J. S.","year":"2005","journal-title":"Blood"},{"issue":"4","key":"e_1_2_8_38_1","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1023\/B:AGEN.0000029410.32264.b0","article-title":"VEGF and Endostatin Levels in Wound Fluid and Plasma After Breast Surgery","volume":"6","author":"Wu F. P. K.","year":"2003","journal-title":"Angiogenesis"},{"issue":"4","key":"e_1_2_8_39_1","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1038\/nrclinonc.2014.224","article-title":"Exploiting the Critical Perioperative Period to Improve Long\u2010Term Cancer Outcomes","volume":"12","author":"Horowitz M.","year":"2015","journal-title":"Nature Reviews Clinical Oncology"},{"issue":"17","key":"e_1_2_8_40_1","doi-asserted-by":"crossref","first-page":"4314","DOI":"10.3390\/cancers15174314","article-title":"Effects of Hyperthermia and Hyperthermic Intraperitoneal Chemoperfusion on the Peritoneal and Tumor Immune Contexture","volume":"15","author":"Chia D. K. A.","year":"2023","journal-title":"Cancers"},{"issue":"4","key":"e_1_2_8_41_1","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1007\/s10585-018-9896-8","article-title":"Potential Impact of Invasive Surgical Procedures on Primary Tumor Growth and Metastasis","volume":"35","author":"Alieva M.","year":"2018","journal-title":"Clinical & Experimental Metastasis"},{"issue":"1","key":"e_1_2_8_42_1","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1186\/s12943-019-1058-3","article-title":"Surgical Stress and Cancer Progression: The Twisted Tango","volume":"18","author":"Chen Z.","year":"2019","journal-title":"Molecular Cancer"},{"issue":"12","key":"e_1_2_8_43_1","doi-asserted-by":"crossref","first-page":"4096","DOI":"10.3390\/jcm9124096","article-title":"Surgical Stress Promotes Tumor Progression: A Focus on the Impact of the Immune Response","volume":"9","author":"Onuma A. E.","year":"2020","journal-title":"Journal of Clinical Medicine"},{"issue":"5","key":"e_1_2_8_44_1","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0155947","article-title":"Surgical Stress Abrogates Pre\u2010Existing Protective T Cell Mediated Anti\u2010Tumor Immunity Leading to Postoperative Cancer Recurrence","volume":"11","author":"Ananth A. A.","year":"2016","journal-title":"PLoS One"},{"key":"e_1_2_8_45_1","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1016\/j.semcancer.2022.01.006","article-title":"Surgery\u2010Mediated Tumor\u2010Promoting Effects on the Immune Microenvironment","volume":"86","author":"Cheng X.","year":"2022","journal-title":"Seminars in Cancer Biology"},{"issue":"1","key":"e_1_2_8_46_1","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1245\/s10434-022-12367-6","article-title":"Relapse of Pseudomyxoma Peritonei After Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy: Pattern of Failure, Clinical Management and Outcomes","volume":"30","author":"Baratti D.","year":"2023","journal-title":"Annals of Surgical Oncology"},{"key":"e_1_2_8_47_1","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.ejca.2018.04.015","article-title":"Peritoneal and Extraperitoneal Relapse After Previous Curative Treatment of Peritoneal Metastases From Colorectal Cancer: What Survival Can We Expect?","volume":"100","author":"Gelli M.","year":"2018","journal-title":"European Journal of Cancer"},{"issue":"10","key":"e_1_2_8_48_1","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1111\/j.1600-0463.2009.02524.x","article-title":"Anti\u2010Angiogenic Factor Endostatin in Osteosarcoma","volume":"117","author":"Kim H. S.","year":"2009","journal-title":"APMIS"},{"key":"e_1_2_8_49_1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2023\/8161683","article-title":"Efficacy of Recombinant Human Endostatin Plus Neoadjuvant Chemotherapy for Osteosarcoma and Its Influence on Serum VEGF and MMP\u20109 Levels","volume":"2023","author":"Sui W.","year":"2023","journal-title":"Journal of Oncology"},{"issue":"1","key":"e_1_2_8_50_1","doi-asserted-by":"crossref","first-page":"166","DOI":"10.20892\/j.issn.2095-3941.2018.0315","article-title":"Perioperative Rh\u2010Endostatin With Chemotherapy Improves the Survival of Conventional Osteosarcoma Patients: A Prospective Non\u2010Randomized Controlled Study","volume":"16","author":"Hairong X.","year":"2019","journal-title":"Cancer Biology & Medicine"},{"issue":"2","key":"e_1_2_8_51_1","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.bbi.2004.07.004","article-title":"Marginating Pulmonary\u2010Nk Activity and Resistance to Experimental Tumor Metastasis: Suppression by Surgery and the Prophylactic Use of a \u03b2\u2010Adrenergic Antagonist and a Prostaglandin Synthesis Inhibitor","volume":"19","author":"Melamed R.","year":"2005","journal-title":"Brain, Behavior, and Immunity"},{"issue":"1","key":"e_1_2_8_52_1","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1186\/s12967-018-1643-z","article-title":"Surgical Peritoneal Stress Creates a Pro\u2010Metastatic Niche Promoting Resistance to Apoptosis via IL\u20108","volume":"16","author":"Pasquier J.","year":"2018","journal-title":"Journal of Translational Medicine"},{"issue":"1","key":"e_1_2_8_53_1","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1158\/0008-5472.CAN-12-1993","article-title":"Preventing Postoperative Metastatic Disease by Inhibiting Surgery\u2010Induced Dysfunction in Natural Killer Cells","volume":"73","author":"Tai L. H.","year":"2013","journal-title":"Cancer Research"},{"issue":"2","key":"e_1_2_8_54_1","doi-asserted-by":"crossref","first-page":"454","DOI":"10.3390\/cells10020454","article-title":"Neuroimmune Regulation of Surgery\u2010Associated Metastases","volume":"10","author":"Shurin M. R.","year":"2021","journal-title":"Cells"},{"issue":"1","key":"e_1_2_8_55_1","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1186\/s12943-019-1058-3","article-title":"Surgical Stress and Cancer Progression: The Twisted Tango","volume":"18","author":"Chen Z.","year":"2019","journal-title":"Molecular cancer"},{"key":"e_1_2_8_56_1","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1202169","article-title":"Targeted Immune Activation in Pediatric Solid Tumors: Opportunities to Complement Local Control Approaches","volume":"14","author":"Vonderhaar E. P.","year":"2023","journal-title":"Frontiers in immunology"},{"key":"e_1_2_8_57_1","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1016\/j.semcancer.2022.01.006","article-title":"Surgery\u2010Mediated Tumor\u2010Promoting Effects on the Immune Microenvironment","volume":"86","author":"Cheng X.","year":"2022","journal-title":"Seminars in Cancer Biology"},{"issue":"10","key":"e_1_2_8_58_1","doi-asserted-by":"crossref","first-page":"2021","DOI":"10.1007\/s00262-020-02596-7","article-title":"Prevention of Liver Metastases Through Perioperative Acute CpG\u2010C Immune Stimulation","volume":"69","author":"Sorski L.","year":"2020","journal-title":"Cancer Immunology, Immunotherapy"},{"issue":"2","key":"e_1_2_8_59_1","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1245\/s10434-006-9078-9","article-title":"Amelioration of Operation\u2010Induced Suppression of Marginating Pulmonary NK Activity Using Poly IC: A Potential Approach to Reduce Postoperative Metastasis","volume":"14","author":"Shakhar G.","year":"2007","journal-title":"Annals of Surgical Oncology"},{"issue":"1","key":"e_1_2_8_60_1","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1158\/0008-5472.CAN-12-1993","article-title":"Preventing Postoperative Metastatic Disease by Inhibiting Surgery\u2010Induced Dysfunction in Natural Killer Cells","volume":"73","author":"Tai L. H.","year":"2013","journal-title":"Cancer Research"},{"key":"e_1_2_8_61_1","first-page":"217","article-title":"Attacking Postoperative Metastases Using Perioperative Oncolytic Viruses and Viral Vaccines","volume":"4","author":"Tai L. H.","year":"2014","journal-title":"Frontiers in Oncology"},{"issue":"18","key":"e_1_2_8_62_1","doi-asserted-by":"crossref","first-page":"5104","DOI":"10.1158\/1078-0432.CCR-13-0246","article-title":"Perioperative Influenza Vaccination Reduces Postoperative Metastatic Disease by Reversing Surgery\u2010Induced Dysfunction in Natural Killer Cells","volume":"19","author":"Tai L. H.","year":"2013","journal-title":"Clinical Cancer Research"},{"issue":"2","key":"e_1_2_8_63_1","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1007\/s10549-007-9540-9","article-title":"Prophylactic IL\u201012 Treatment Reduces Postoperative Metastasis: Mediation by Increased Numbers but Not Cytotoxicity of NK Cells","volume":"107","author":"Schwartz Y.","year":"2008","journal-title":"Breast Cancer Research and Treatment"},{"issue":"7","key":"e_1_2_8_64_1","doi-asserted-by":"crossref","first-page":"2042","DOI":"10.1245\/s10434-008-9890-5","article-title":"Perioperative Use of \u03b2\u2010blockers and COX\u20102 Inhibitors May Improve Immune Competence and Reduce the Risk of Tumor Metastasis","volume":"15","author":"Benish M.","year":"2008","journal-title":"Annals of Surgical Oncology"},{"key":"e_1_2_8_65_1","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1016\/j.ccell.2022.04.006","article-title":"Regional CAR T Cell Therapy: An Ignition Key for Systemic Immunity in Solid Tumors","volume":"40","author":"Cherkassky L.","year":"2022","journal-title":"Cancer Cell"},{"issue":"5","key":"e_1_2_8_66_1","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1038\/cgt.2016.14","article-title":"Regional CAR\u2010T Cell Infusions for Peritoneal Carcinomatosis Are Superior to Systemic Delivery","volume":"23","author":"Katz S. C.","year":"2016","journal-title":"Cancer Gene Therapy"},{"issue":"4","key":"e_1_2_8_67_1","doi-asserted-by":"crossref","first-page":"2194","DOI":"10.1245\/s10434-023-14858-6","article-title":"Reconnaissance for Intraperitoneal Immunotherapy","volume":"31","author":"Levine E. A.","year":"2024","journal-title":"Annals of Surgical Oncology"},{"issue":"20","key":"e_1_2_8_68_1","doi-asserted-by":"crossref","first-page":"4649","DOI":"10.3390\/jcm10204649","article-title":"Immunotherapy for Peritoneal Metastases From Gastric Cancer: Rationale, Current Practice and Ongoing Trials","volume":"10","author":"Ruiz Hisp\u00e1n E.","year":"2021","journal-title":"Journal of Clinical Medicine"},{"key":"e_1_2_8_69_1","doi-asserted-by":"publisher","DOI":"10.3390\/antib9030034"},{"issue":"6","key":"e_1_2_8_70_1","doi-asserted-by":"crossref","first-page":"1610","DOI":"10.3390\/biomedicines11061610","article-title":"Mechanisms of Action and Limitations of Monoclonal Antibodies and Single Chain Fragment Variable (scFSv) in the Treatment of Cancer","volume":"11","author":"Rodr\u00edguez\u2010Nava C.","year":"2023","journal-title":"Biomedicines"},{"issue":"18","key":"e_1_2_8_71_1","doi-asserted-by":"crossref","first-page":"4641","DOI":"10.1158\/0008-5472.CAN-21-1109","article-title":"Mechanisms of Therapeutic Antitumor Monoclonal Antibodies","volume":"81","author":"Tsao L. C.","year":"2021","journal-title":"Cancer Research"},{"issue":"1","key":"e_1_2_8_72_1","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.semcancer.2011.12.009","article-title":"Monoclonal Antibodies for the Treatment of Cancer","volume":"22","author":"Shuptrine C. W.","year":"2012","journal-title":"Seminars in Cancer Biology"},{"issue":"8","key":"e_1_2_8_73_1","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1038\/s41573-023-00709-2","article-title":"Antibody\u2013Drug Conjugates Come of Age in Oncology","volume":"22","author":"Dumontet C.","year":"2023","journal-title":"Nature Reviews Drug Discovery"},{"issue":"20","key":"e_1_2_8_74_1","doi-asserted-by":"crossref","first-page":"4764","DOI":"10.3390\/molecules25204764","article-title":"Antibody\u2010Drug Conjugates for Cancer Therapy","volume":"25","author":"Hafeez U.","year":"2020","journal-title":"Molecules"},{"issue":"3","key":"e_1_2_8_75_1","doi-asserted-by":"crossref","first-page":"655","DOI":"10.3390\/biomedicines10030655","article-title":"Assessing the Future of Solid Tumor Immunotherapy","volume":"10","author":"Guha P.","year":"2022","journal-title":"Biomedicines"},{"key":"e_1_2_8_76_1","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1007\/978-1-4939-3684-7_28","article-title":"Generation of BiKEs and TriKEs to Improve NK Cell\u2010Mediated Targeting of Tumor Cells","volume":"1441","author":"Felices M.","year":"2016","journal-title":"Methods in molecular biology (Clifton, N.J.)"},{"issue":"14","key":"e_1_2_8_77_1","doi-asserted-by":"crossref","first-page":"3192","DOI":"10.1002\/cncr.32909","article-title":"The BITE (Bispecific T\u2010Cell Engager) Platform: Development and Future Potential of a Targeted Immuno\u2010Oncology Therapy Across Tumor Types","volume":"126","author":"Einsele H.","year":"2020","journal-title":"Cancer"},{"key":"e_1_2_8_78_1","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1002\/path.3000","article-title":"Anoikis: An Emerging Hallmark in Health and Diseases","volume":"226","author":"Taddei M.","year":"2012","journal-title":"The Journal of Pathology"},{"issue":"9","key":"e_1_2_8_79_1","doi-asserted-by":"crossref","first-page":"1592","DOI":"10.1111\/ans.15796","article-title":"Colorectal Peritoneal Metastases: Pathogenesis, Diagnosis and Treatment Options \u2013 An Evidence\u2010Based Update","volume":"90","author":"Narasimhan V.","year":"2020","journal-title":"ANZ journal of surgery"},{"issue":"5","key":"e_1_2_8_80_1","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1007\/s10585-016-9791-0","article-title":"Adhesion Molecules in Peritoneal Dissemination: Function, Prognostic Relevance and Therapeutic Options","volume":"33","author":"Sluiter N.","year":"2016","journal-title":"Clinical & Experimental Metastasis"},{"issue":"5","key":"e_1_2_8_81_1","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.2353\/ajpath.2006.051222","article-title":"Preferential Attachment of Peritoneal Tumor Metastases to Omental Immune Aggregates and Possible Role of a Unique Vascular Microenvironment in Metastatic Survival and Growth","volume":"169","author":"Gerber S. A.","year":"2006","journal-title":"The American Journal of Pathology"},{"key":"e_1_2_8_82_1","doi-asserted-by":"publisher","DOI":"10.15252\/emmm.202215914"},{"key":"e_1_2_8_83_1","doi-asserted-by":"crossref","first-page":"2120","DOI":"10.3389\/fimmu.2019.02120","article-title":"Altered Cell Adhesion and Glycosylation Promote Cancer Immune Suppression and Metastasis","volume":"10","author":"L\u00e4ubli H.","year":"2019","journal-title":"Frontiers in immunology"},{"issue":"2","key":"e_1_2_8_84_1","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1080\/14737140.2018.1418326","article-title":"Peritoneal Dissemination of Ovarian Cancer: Role of MUC16\u2010Mesothelin Interaction and Implications for Treatment","volume":"18","author":"Coelho R.","year":"2018","journal-title":"Expert Review of Anticancer Therapy"},{"key":"e_1_2_8_85_1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14061550"},{"issue":"34","key":"e_1_2_8_86_1","doi-asserted-by":"crossref","first-page":"4171","DOI":"10.1200\/JCO.2016.68.3672","article-title":"Mesothelin Immunotherapy for Cancer: Ready for Prime Time?","volume":"34","author":"Hassan R.","year":"2016","journal-title":"Journal of Clinical Oncology"},{"issue":"6","key":"e_1_2_8_87_1","doi-asserted-by":"crossref","first-page":"1550","DOI":"10.3390\/cancers14061550","article-title":"Mesothelin: An Immunotherapeutic Target Beyond Solid Tumors","volume":"14","author":"Faust J. R.","year":"2022","journal-title":"Cancers"},{"key":"e_1_2_8_88_1","doi-asserted-by":"crossref","first-page":"1870","DOI":"10.1038\/srep01870","article-title":"Mesothelin Binding to CA125\/MUC16 Promotes Pancreatic Cancer Cell Motility and Invasion via MMP\u20107 Activation","volume":"3","author":"Chen S. H.","year":"2013","journal-title":"Scientific Reports"},{"issue":"26","key":"e_1_2_8_89_1","doi-asserted-by":"crossref","first-page":"11079","DOI":"10.1074\/jbc.M116.770123","article-title":"N\u2010Glycosylation Affects the Stability and Barrier Function of the MUC16 Mucin","volume":"292","author":"Taniguchi T.","year":"2017","journal-title":"Journal of Biological Chemistry"},{"issue":"1","key":"e_1_2_8_90_1","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1186\/1476-4598-5-50","article-title":"Mesothelin\u2010MUC16 Binding Is a High Affinity, N\u2010Glycan Dependent Interaction That Facilitates Peritoneal Metastasis of Ovarian Tumors","volume":"5","author":"Gubbels J. A.","year":"2006","journal-title":"Molecular cancer"},{"issue":"1","key":"e_1_2_8_91_1","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1007\/s10238-024-01365-5","article-title":"MUC16: Clinical Targets With Great Potential","volume":"24","author":"Zhang X. Y.","year":"2024","journal-title":"Clinical and Experimental Medicine"},{"issue":"3","key":"e_1_2_8_92_1","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1097\/PAI.0b013e3181c925aa","article-title":"MUC16 Expression and Risk of Adenocarcinoma Metastases to Peritoneum, Pleura, Leptomeninges, and Brain","volume":"18","author":"Johnson M. D.","year":"2010","journal-title":"Applied Immunohistochemistry & Molecular Morphology"},{"issue":"1","key":"e_1_2_8_93_1","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1186\/s12885-019-5611-7","article-title":"Ascites From Ovarian Cancer Patients Stimulates MUC16 Mucin Expression and Secretion in Human Peritoneal Mesothelial Cells Through An Akt\u2010Dependent Pathway","volume":"19","author":"Matte I.","year":"2019","journal-title":"BMC Cancer"},{"key":"e_1_2_8_94_1","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/1476-4598-9-11","article-title":"MUC16 Provides Immune Protection by Inhibiting Synapse Formation Between NK and Ovarian Tumor Cells","volume":"9","author":"Gubbels J. A.","year":"2010","journal-title":"Molecular cancer"},{"issue":"7","key":"e_1_2_8_95_1","doi-asserted-by":"crossref","DOI":"10.1177\/1010428319860728","article-title":"Mucin 16 and Kallikrein 13 as Potential Prognostic Factors in Colon Cancer: Results of an Oncological 92\u2010multiplex Immunoassay","volume":"41","author":"Bj\u00f6rkman K.","year":"2019","journal-title":"Tumor Biology"},{"key":"e_1_2_8_96_1","doi-asserted-by":"crossref","DOI":"10.1016\/j.omto.2023.100756","article-title":"Targeting Mesothelin in Cancer","volume":"31","author":"Elbi C.","year":"2023","journal-title":"Molecular Therapy \u2010 Oncolytics"},{"issue":"1","key":"e_1_2_8_97_1","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1186\/1756-9966-31-84","article-title":"Mesothelin Regulates Growth and Apoptosis in Pancreatic Cancer Cells Through p53\u2010Dependent and \u2010Independent Signal Pathway","volume":"31","author":"Zheng C.","year":"2012","journal-title":"Journal of Experimental & Clinical Cancer Research"},{"issue":"2","key":"e_1_2_8_98_1","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1067\/msy.2000.101584","article-title":"Inflammatory Cytokines and Cell Response in Surgery","volume":"127","author":"Lin E.","year":"2000","journal-title":"Surgery"},{"issue":"3","key":"e_1_2_8_99_1","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1002\/1097-0142(19920801)70:3<709::AID-CNCR2820700328>3.0.CO;2-O","article-title":"Preoperative and Postoperative Cytokines in Patients With Cancer","volume":"70","author":"Nakazaki H.","year":"1992","journal-title":"Cancer"},{"issue":"2","key":"e_1_2_8_100_1","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1177\/0885066610384188","article-title":"Interleukin\u20106 in Surgery, Trauma, and Critical Care Part Ii: Clinical Implications","volume":"26","author":"Jawa R. S.","year":"2011","journal-title":"Journal of Intensive Care Medicine"},{"issue":"1","key":"e_1_2_8_101_1","doi-asserted-by":"crossref","first-page":"6218","DOI":"10.1038\/s41467-021-26407-4","article-title":"Microenvironmental IL\u20106 Inhibits Anti\u2010Cancer Immune Responses Generated by Cytotoxic Chemotherapy","volume":"12","author":"Bent E. H.","year":"2021","journal-title":"Nature Communications"},{"issue":"11","key":"e_1_2_8_102_1","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2023-007530","article-title":"New Perspectives in Cancer Immunotherapy: Targeting IL\u20106 Cytokine Family","volume":"11","author":"Soler M. F.","year":"2023","journal-title":"Journal for Immunotherapy of Cancer"},{"issue":"1","key":"e_1_2_8_103_1","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.smim.2014.01.008","article-title":"The Two Faces of IL\u20106 in the Tumor Microenvironment","volume":"26","author":"Fisher D. T.","year":"2014","journal-title":"Seminars in Immunology"},{"key":"e_1_2_8_104_1","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.bbi.2023.01.005","article-title":"Perioperative Escape From Dormancy of Spontaneous Micro\u2010Metastases: A Role for Malignant Secretion of IL\u20106, IL\u20108, and VEGF, Through Adrenergic and Prostaglandin Signaling","volume":"109","author":"Haldar R.","year":"2023","journal-title":"Brain, Behavior, and Immunity"},{"key":"e_1_2_8_105_1","doi-asserted-by":"publisher","DOI":"10.1097\/SLA.0000000000005997"},{"issue":"1","key":"e_1_2_8_106_1","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1186\/s40425-019-0708-8","article-title":"Comprehensive Immune Profiling and Immune\u2010Monitoring Using Body Fluid of Patients With Metastatic Gastric Cancer","volume":"7","author":"Park H. S.","year":"2019","journal-title":"Journal for Immunotherapy of Cancer"},{"key":"e_1_2_8_107_1","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-023-14553-6"},{"key":"e_1_2_8_108_1","doi-asserted-by":"crossref","first-page":"3645","DOI":"10.2147\/OTT.S134584","article-title":"Clinical Targeting Recombinant Immunotoxins for Cancer Therapy","volume":"10","author":"Li M.","year":"2017","journal-title":"OncoTargets and Therapy"},{"issue":"1","key":"e_1_2_8_109_1","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1186\/s12885-020-07722-3","article-title":"Mesothelin Blockage by Amatuximab Suppresses Cell Invasiveness, Enhances Gemcitabine Sensitivity and Regulates Cancer Cell Stemness in Mesothelin\u2010Positive Pancreatic Cancer Cells","volume":"21","author":"Matsuzawa F.","year":"2021","journal-title":"BMC Cancer"},{"issue":"22","key":"e_1_2_8_110_1","doi-asserted-by":"crossref","first-page":"4936","DOI":"10.1002\/cncr.33145","article-title":"Phase 1 Study of the Immunotoxin LMB\u2010100 in Patients With Mesothelioma and Other Solid Tumors Expressing Mesothelin","volume":"126","author":"Hassan R.","year":"2020","journal-title":"Cancer"},{"key":"e_1_2_8_111_1","doi-asserted-by":"crossref","first-page":"1824","DOI":"10.1200\/JCO.19.02085","article-title":"First\u2010In\u2010Human, Multicenter, Phase I Dose\u2010Escalation and Expansion Study of Anti\u2010Mesothelin Antibody\u2010Drug Conjugate Anetumab Ravtansine in Advanced or Metastatic Solid Tumors","volume":"38","author":"Hassan R.","year":"2020","journal-title":"Journal of Clinical Oncology"},{"issue":"1","key":"e_1_2_8_112_1","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1186\/s12885-021-08239-z","article-title":"Cancer\u2010Associated Mutations Reveal a Novel Role for Epcam as An Inhibitor of Cathepsin\u2010L and Tumor Cell Invasion","volume":"21","author":"Sankpal N. V.","year":"2021","journal-title":"BMC Cancer"},{"issue":"5","key":"e_1_2_8_113_1","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.21037\/tlcr-22-801","article-title":"Clinical and Prognostic Significance of Detecting CEA, EGFR, LunX, c\u2010met and EpCAM mRNA\u2010Positive Cells in the Peripheral Blood, Tumor\u2010Draining Blood and Bone Marrow of Non\u2010Small Cell Lung Cancer Patients","volume":"12","author":"Rehulkova A.","year":"2023","journal-title":"Translational Lung Cancer Research"},{"issue":"1","key":"e_1_2_8_114_1","doi-asserted-by":"crossref","first-page":"19","DOI":"10.3390\/cancers10010019","article-title":"EpCAM Immunotherapy Versus Specific Targeted Delivery of Drugs","volume":"10","author":"Macdonald J.","year":"2018","journal-title":"Cancers"},{"issue":"4","key":"e_1_2_8_115_1","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1080\/0284186X.2019.1704864","article-title":"Immune Stimulatory Effect of Anti\u2010EpCAM Immunotoxin\u2013Improved Overall Survival of Metastatic Colorectal Cancer Patients","volume":"59","author":"Andersson Y.","year":"2020","journal-title":"Acta Oncologica"},{"key":"e_1_2_8_116_1","unstructured":"E.Billmann Thorgersen J.Asvall I.Storhaug Fr\u00f8ysnes et al. Increased Local Inflammatory Response to MOC31PE Immunotoxin After Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy. Available from:https:\/\/doi.org\/10.1245\/s10434-."},{"key":"e_1_2_8_117_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-021-01084-4"},{"key":"e_1_2_8_118_1","first-page":"1771","article-title":"Functions of Epcam in Physiological Processes and Diseases (Review)","volume":"42","author":"Huang L.","year":"2018","journal-title":"International Journal of Molecular Medicine. Spandidos Publications"},{"issue":"3","key":"e_1_2_8_119_1","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1038\/s41416-018-0150-6","article-title":"Randomised Phase Ii Trial to Investigate Catumaxomab (Anti\u2010Epcam\u2009\u00d7\u2009anti\u2010CD3) for Treatment of Peritoneal Carcinomatosis in Patients With Gastric Cancer","volume":"119","author":"Kn\u00f6dler M.","year":"2018","journal-title":"British Journal of Cancer"},{"key":"e_1_2_8_120_1","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejps.2020.105584","article-title":"Mechanistic Prediction of First\u2010In\u2010Human Dose for Bispecific CD3\/EpCAM T\u2010Cell Engager Antibody M701, Using An Integrated PK\/PD Modeling Method","volume":"158","author":"Song L.","year":"2021","journal-title":"European Journal of Pharmaceutical Sciences"},{"issue":"9","key":"e_1_2_8_121_1","doi-asserted-by":"crossref","first-page":"2209","DOI":"10.1002\/ijc.25423","article-title":"The Trifunctional Antibody Catumaxomab for the Treatment of Malignant Ascites Due to Epithelial Cancer: Results of a Prospective Randomized Phase II\/III Trial","volume":"127","author":"Heiss M. M.","year":"2010","journal-title":"International Journal of Cancer"},{"key":"e_1_2_8_122_1","doi-asserted-by":"publisher","DOI":"10.1002\/mba2.20"},{"key":"e_1_2_8_123_1","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202204654"},{"issue":"9","key":"e_1_2_8_124_1","doi-asserted-by":"crossref","first-page":"1745","DOI":"10.1007\/s00018-019-03351-7","article-title":"Tumor Angiogenesis: Causes, Consequences, Challenges and Opportunities","volume":"77","author":"Lugano R.","year":"2020","journal-title":"Cellular and Molecular Life Sciences"},{"issue":"5","key":"e_1_2_8_125_1","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.3390\/cancers12051172","article-title":"Inducing Angiogenesis, a Key Step in Cancer Vascularization, and Treatment Approaches","volume":"12","author":"Saman H.","year":"2020","journal-title":"Cancers"},{"issue":"8","key":"e_1_2_8_126_1","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1111\/IGC.0b013e3181b7a40e","article-title":"Study of T Lymphocytes Infiltrating Peritoneal Metastases in Advanced Ovarian Cancer","volume":"19","author":"Tsiatas M. L.","year":"2009","journal-title":"International Journal of Gynecological Cancer"},{"key":"e_1_2_8_127_1","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2020.102017","article-title":"Bevacizumab (Avastin\u00ae) in Cancer Treatment: A Review of 15 Years of Clinical Experience and Future Outlook","volume":"86","author":"Garcia J.","year":"2020","journal-title":"Cancer Treatment Reviews"},{"issue":"6","key":"e_1_2_8_128_1","doi-asserted-by":"crossref","first-page":"1792","DOI":"10.1245\/s10434-013-3442-3","article-title":"Bevacizumab Doubles the Early Postoperative Complication Rate After Cytoreductive Surgery With Hyperthermic Intraperitoneal Chemotherapy (Hipec) for Peritoneal Carcinomatosis of Colorectal Origin","volume":"21","author":"Eveno C.","year":"2014","journal-title":"Annals of Surgical Oncology"},{"key":"e_1_2_8_129_1","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.12666"},{"key":"e_1_2_8_130_1","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.610572"},{"issue":"2","key":"e_1_2_8_131_1","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1007\/s11605-015-2995-9","article-title":"Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) With Low\u2010Dose Cisplatin and Doxorubicin in Gastric Peritoneal Metastasis","volume":"20","author":"Nadiradze G.","year":"2016","journal-title":"Journal of Gastrointestinal Surgery"},{"issue":"1","key":"e_1_2_8_132_1","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1007\/s10555-012-9351-2","article-title":"Cell\u2010Cell and Cell\u2010Matrix Dynamics in Intraperitoneal Cancer Metastasis","volume":"31","author":"Sodek K. L.","year":"2012","journal-title":"Cancer and Metastasis Reviews"},{"issue":"7","key":"e_1_2_8_133_1","doi-asserted-by":"crossref","first-page":"1548","DOI":"10.1158\/0008-5472.CAN-16-1536","article-title":"Surgery for Cancer: A Trigger for Metastases","volume":"77","author":"Tohme S.","year":"2017","journal-title":"Cancer Research"},{"issue":"23","key":"e_1_2_8_134_1","doi-asserted-by":"crossref","first-page":"5641","DOI":"10.3390\/cancers15235641","article-title":"Peritoneal Metastasis: A Dilemma and Challenge in the Treatment of Metastatic Colorectal Cancer","volume":"15","author":"Xia W.","year":"2023","journal-title":"Cancers"},{"issue":"6","key":"e_1_2_8_135_1","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1007\/s004230050246","article-title":"Management of Peritoneal\u2010Surface Malignancy: The Surgeon's Role","volume":"384","author":"Sugarbaker P. H.","year":"1999","journal-title":"Langenbeck's Archives of Surgery"},{"issue":"2","key":"e_1_2_8_136_1","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1002\/path.6170","article-title":"Targeting Carcinoma\u2010Associated Mesothelial Cells With Antibody\u2013Drug Conjugates in Ovarian Carcinomatosis","volume":"261","author":"Pascual\u2010Ant\u00f3n L.","year":"2023","journal-title":"The Journal of Pathology"},{"issue":"13","key":"e_1_2_8_137_1","doi-asserted-by":"crossref","first-page":"3420","DOI":"10.1158\/1078-0432.CCR-19-2238","article-title":"OMTX705, a Novel FAP\u2010Targeting ADC Demonstrates Activity in Chemotherapy and Pembrolizumab\u2010Resistant Solid Tumor Models","volume":"26","author":"Fabre M.","year":"2020","journal-title":"Clinical Cancer Research"},{"key":"e_1_2_8_138_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.00681"},{"issue":"10","key":"e_1_2_8_139_1","doi-asserted-by":"crossref","first-page":"11149","DOI":"10.1002\/cam4.5698","article-title":"Role of Tumor Microenvironment in Cancer Progression and Therapeutic Strategy","volume":"12","author":"Wang Q.","year":"2023","journal-title":"Cancer Medicine"},{"issue":"11","key":"e_1_2_8_140_1","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1038\/s41577-020-0306-5","article-title":"A Guide to Cancer Immunotherapy: From T Cell Basic Science to Clinical Practice","volume":"20","author":"Waldman A. D.","year":"2020","journal-title":"Nature Reviews Immunology"},{"issue":"1","key":"e_1_2_8_141_1","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1186\/s40425-019-0816-5","article-title":"High Expression of B7\u2010H3 on Stromal Cells Defines Tumor and Stromal Compartments in Epithelial Ovarian Cancer and Is Associated With Limited Immune Activation","volume":"7","author":"MacGregor H. L.","year":"2019","journal-title":"Journal for Immunotherapy of Cancer"},{"key":"e_1_2_8_142_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.20.01974"},{"issue":"8","key":"e_1_2_8_143_1","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.3390\/ph15081034","article-title":"Residual Microscopic Peritoneal Metastases After Macroscopic Complete Cytoreductive Surgery for Advanced High\u2010Grade Serous Ovarian Carcinoma: A Target for Folate Receptor Targeted Photodynamic Therapy?","volume":"15","author":"Moinard M.","year":"2022","journal-title":"Pharmaceuticals"},{"key":"e_1_2_8_144_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-022-01247-x"},{"issue":"4","key":"e_1_2_8_145_1","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1038\/s41571-020-00460-2","article-title":"Advances in the Development of Personalized Neoantigen\u2010Based Therapeutic Cancer Vaccines","volume":"18","author":"Blass E.","year":"2021","journal-title":"Nature Reviews Clinical Oncology"},{"key":"e_1_2_8_146_1","doi-asserted-by":"crossref","first-page":"2808","DOI":"10.1158\/1078-0432.CCR-22-2595","article-title":"Maveropepimut\u2010S, a DPX\u2010Based Immune\u2010Educating Therapy, Shows Promising and Durable Clinical Benefit in Patients With Recurrent Ovarian Cancer, a Phase II Trial","volume":"29","author":"Dorigo O.","year":"2023","journal-title":"Clinical Cancer Research"},{"issue":"4","key":"e_1_2_8_147_1","doi-asserted-by":"crossref","first-page":"389","DOI":"10.4103\/0971-5916.159250","article-title":"Survivin: A Molecular Biomarker in Cancer","volume":"141","author":"Mittal R.","year":"2015","journal-title":"Indian Journal of Medical Research"},{"issue":"1","key":"e_1_2_8_148_1","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1186\/s12935-016-0326-1","article-title":"Survivin: A Unique Target for Tumor Therapy","volume":"16","author":"Garg H.","year":"2016","journal-title":"Cancer Cell International"},{"issue":"2","key":"e_1_2_8_149_1","doi-asserted-by":"crossref","first-page":"393","DOI":"10.3390\/cancers15020393","article-title":"WT1 Trio Peptide\u2010Based Cancer Vaccine for Rare Cancers Expressing Shared Target WT1","volume":"15","author":"Oji Y.","year":"2023","journal-title":"Cancers"},{"key":"e_1_2_8_150_1","doi-asserted-by":"publisher","DOI":"10.21873\/anticanres.12464"},{"issue":"4","key":"e_1_2_8_151_1","doi-asserted-by":"crossref","first-page":"165","DOI":"10.36401\/JIPO-20-12","article-title":"Wilms\u2019 Tumor 1 (WT1): The Vaccine for Cancer","volume":"3","author":"Hein K. Z.","year":"2020","journal-title":"Journal of Immunotherapy and Precision Oncology"},{"key":"e_1_2_8_152_1","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.945867"},{"issue":"3","key":"e_1_2_8_153_1","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1038\/mt.2011.269","article-title":"Phase I Trial of \u201cBi\u2010shRNAifurin\/GMCSF DNAa\/Autologous Tumor Cell\u201d Vaccine (FANG) in Advanced Cancer","volume":"20","author":"Senzer N.","year":"2012","journal-title":"Molecular Therapy"},{"issue":"10","key":"e_1_2_8_154_1","doi-asserted-by":"crossref","first-page":"e450","DOI":"10.1016\/S1470-2045(22)00372-2","article-title":"Clinical Advances and Ongoing Trials of mRNA Vaccines for Cancer Treatment","volume":"23","author":"Lorentzen C. L.","year":"2022","journal-title":"The lancet oncology"},{"issue":"7","key":"e_1_2_8_155_1","doi-asserted-by":"crossref","first-page":"2969","DOI":"10.1016\/j.apsb.2022.03.011","article-title":"mRNA Cancer Vaccines: Advances, Trends and Challenges","volume":"12","author":"He Q.","year":"2022","journal-title":"Acta Pharmaceutica Sinica B"},{"issue":"7963","key":"e_1_2_8_156_1","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1038\/s41586-023-06063-y","article-title":"Personalized Rna Neoantigen Vaccines Stimulate T Cells in Pancreatic Cancer","volume":"618","author":"Rojas L. A.","year":"2023","journal-title":"Nature"},{"issue":"6","key":"e_1_2_8_157_1","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1038\/s41568-021-00346-0","article-title":"Therapeutic Cancer Vaccines","volume":"21","author":"Saxena M.","year":"2021","journal-title":"Nature Reviews Cancer"},{"issue":"8","key":"e_1_2_8_158_1","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2023-007070","article-title":"Adjuvant Dendritic Cell\u2010Based Immunotherapy After Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy in Patients With Malignant Peritoneal Mesothelioma: A Phase II Clinical Trial","volume":"11","author":"Dietz M. V.","year":"2023","journal-title":"Journal for Immunotherapy of Cancer"},{"issue":"3","key":"e_1_2_8_159_1","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1016\/j.ejso.2022.10.003","article-title":"Impact of Centralization of Care for Malignant Peritoneal Mesothelioma: A Historical Cohort Study From the Dutch Mesothelioma Expert Centers","volume":"49","author":"Kooten J. P.","year":"2023","journal-title":"European Journal of Surgical Oncology"},{"issue":"1","key":"e_1_2_8_160_1","doi-asserted-by":"crossref","first-page":"5173","DOI":"10.1038\/s41467-020-18962-z","article-title":"Th17\u2010inducing Autologous Dendritic Cell Vaccination Promotes Antigen\u2010Specific Cellular and Humoral Immunity in Ovarian Cancer Patients","volume":"11","author":"Block M. S.","year":"2020","journal-title":"Nature Communications"},{"key":"e_1_2_8_161_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1090533"},{"issue":"1","key":"e_1_2_8_162_1","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1038\/s41392-023-01674-3","article-title":"Therapeutic Cancer Vaccines: Advancements, Challenges, and Prospects","volume":"8","author":"Fan T.","year":"2023","journal-title":"Signal Transduction and Targeted Therapy"},{"key":"e_1_2_8_163_1","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.584367"},{"key":"e_1_2_8_164_1","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.omto.2021.05.002","article-title":"Current Strategies in Engaging Oncolytic Viruses With Antitumor Immunity","volume":"22","author":"Boagni D. A.","year":"2021","journal-title":"Molecular Therapy \u2010 Oncolytics"},{"key":"e_1_2_8_165_1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.cytogfr.2023.01.002","article-title":"Preexisting Immunity: Barrier or Bridge to Effective Oncolytic Virus Therapy?","volume":"70","author":"Groeneveldt C.","year":"2023","journal-title":"Cytokine & Growth Factor Reviews"},{"issue":"1","key":"e_1_2_8_166_1","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1038\/s41392-023-01407-6","article-title":"Oncolytic Virotherapy: Basic Principles, Recent Advances and Future Directions","volume":"8","author":"Lin D.","year":"2023","journal-title":"Signal Transduction and Targeted Therapy"},{"issue":"10","key":"e_1_2_8_167_1","doi-asserted-by":"crossref","first-page":"2920","DOI":"10.1016\/j.ymthe.2021.05.015","article-title":"Local Oncolytic Adenovirotherapy Produces An Abscopal Effect via Tumor\u2010Derived Extracellular Vesicles","volume":"29","author":"Kakiuchi Y.","year":"2021","journal-title":"Molecular Therapy"},{"issue":"6","key":"e_1_2_8_168_1","doi-asserted-by":"crossref","DOI":"10.1002\/rmv.2008","article-title":"Defects in Interferon Pathways as Potential Biomarkers of Sensitivity to Oncolytic Viruses","volume":"28","author":"Matveeva O. V.","year":"2018","journal-title":"Reviews in Medical Virology"},{"issue":"7","key":"e_1_2_8_169_1","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1038\/77558","article-title":"Exploiting Tumor\u2010Specific Defects in the Interferon Pathway With a Previously Unknown Oncolytic Virus","volume":"6","author":"Stojdl D. F.","year":"2000","journal-title":"Nature Medicine"},{"key":"e_1_2_8_170_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.971674"},{"key":"e_1_2_8_171_1","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/j.omtm.2020.01.001","article-title":"Oncolytic Viruses and the Immune System: The Dynamic Duo","volume":"17","author":"Lemos de Matos A.","year":"2020","journal-title":"Molecular Therapy \u2010 Methods & Clinical Development"},{"issue":"4","key":"e_1_2_8_172_1","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/S1535-6108(03)00241-1","article-title":"Vsv Strains With Defects in Their Ability to Shutdown Innate Immunity Are Potent Systemic Anti\u2010Cancer Agents","volume":"4","author":"Stojdl D. F.","year":"2003","journal-title":"Cancer Cell"},{"issue":"8","key":"e_1_2_8_173_1","doi-asserted-by":"crossref","first-page":"3835","DOI":"10.1128\/JVI.01553-09","article-title":"Type I Interferon\u2010Sensitive Recombinant Newcastle Disease Virus for Oncolytic Virotherapy","volume":"84","author":"Elankumaran S.","year":"2010","journal-title":"Journal of Virology"},{"issue":"1","key":"e_1_2_8_174_1","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1038\/s41392-022-00951-x","article-title":"Engineering Strategies to Enhance Oncolytic Viruses in Cancer Immunotherapy","volume":"7","author":"Tian Y.","year":"2022","journal-title":"Signal Transduction and Targeted Therapy"},{"issue":"7","key":"e_1_2_8_175_1","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2019.1591875","article-title":"Oncolytic Virus Immunotherapy Induces Immunogenic Cell Death and Overcomes Sting Deficiency in Melanoma","volume":"8","author":"Bommareddy P. K.","year":"2019","journal-title":"Oncoimmunology"},{"key":"e_1_2_8_176_1","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.761015"},{"issue":"12","key":"e_1_2_8_177_1","doi-asserted-by":"crossref","first-page":"6506","DOI":"10.3390\/v7122953","article-title":"Dendritic Cells in Oncolytic Virus\u2010Based Anti\u2010Cancer Therapy","volume":"7","author":"Kim Y.","year":"2015","journal-title":"Viruses"},{"issue":"2","key":"e_1_2_8_178_1","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.3390\/ijms25021180","article-title":"Oncolytic Virotherapy: A New Paradigm in Cancer Immunotherapy","volume":"25","author":"Volovat S. R.","year":"2024","journal-title":"International Journal of Molecular Sciences"},{"issue":"11","key":"e_1_2_8_179_1","doi-asserted-by":"crossref","first-page":"2769","DOI":"10.3390\/cancers14112769","article-title":"Hydrad: A Helper\u2010Dependent Adenovirus Targeting Multiple Immune Pathways for Cancer Immunotherapy","volume":"14","author":"Rosewell Shaw A.","year":"2022","journal-title":"Cancers"},{"issue":"8","key":"e_1_2_8_180_1","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1038\/s41577-018-0014-6","article-title":"Integrating Oncolytic Viruses in Combination Cancer Immunotherapy","volume":"18","author":"Bommareddy P. K.","year":"2018","journal-title":"Nature Reviews Immunology"},{"key":"e_1_2_8_181_1","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.ade6790"},{"key":"e_1_2_8_182_1","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.omto.2022.03.003","article-title":"Intraperitoneal Oncolytic Virotherapy for Patients With Malignant Ascites: Characterization of Clinical Efficacy and Antitumor Immune Response","volume":"25","author":"Zhang Y.","year":"2022","journal-title":"Molecular Therapy \u2010 Oncolytics"},{"issue":"8","key":"e_1_2_8_183_1","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.15252\/emmm.201707567","article-title":"Oncolytic Adenovirus Expressing Bispecific Antibody Targets T\u2010Cell Cytotoxicity in Cancer Biopsies","volume":"9","author":"Freedman J. D.","year":"2017","journal-title":"EMBO Molecular Medicine"},{"issue":"4","key":"e_1_2_8_184_1","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2022-006280","article-title":"Development of the Oncolytic Virus, CF33, and Its Derivatives for Peritoneal\u2010Directed Treatment of Gastric Cancer Peritoneal Metastases","volume":"11","author":"Yang A.","year":"2023","journal-title":"Journal for Immunotherapy of Cancer"},{"issue":"1","key":"e_1_2_8_185_1","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1186\/s42490-019-0016-x","article-title":"Overcoming the Limitations of Locally Administered Oncolytic Virotherapy","volume":"1","author":"Hong J.","year":"2019","journal-title":"BMC Biomedical Engineering"},{"issue":"4","key":"e_1_2_8_186_1","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1016\/S1470-2045(24)00079-2","article-title":"LOAd703, An Oncolytic Virus\u2010Based Immunostimulatory Gene Therapy, Combined With Chemotherapy for Unresectable or Metastatic Pancreatic Cancer (LOKON001): Results From Arm 1 of a Non\u2010Randomised, Single\u2010Centre, Phase 1\/2 Study","volume":"25","author":"Musher B. L.","year":"2024","journal-title":"The Lancet Oncology"},{"issue":"2","key":"e_1_2_8_187_1","doi-asserted-by":"crossref","first-page":"363","DOI":"10.3390\/v15020363","article-title":"Establishing a New Platform to Investigate the Efficacy of Oncolytic Virotherapy in a Human Ex Vivo Peritoneal Carcinomatosis Model","volume":"15","author":"Koch J.","year":"2023","journal-title":"Viruses"},{"issue":"3","key":"e_1_2_8_188_1","doi-asserted-by":"crossref","first-page":"F433","DOI":"10.1152\/ajprenal.00313.2004","article-title":"The Transport Barrier in Intraperitoneal Therapy","volume":"288","author":"Flessner M. F.","year":"2005","journal-title":"American Journal of Physiology\u2010Renal Physiology"},{"issue":"3","key":"e_1_2_8_189_1","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1515\/pp-2016-0015","article-title":"Functional Vascular Anatomy of the Peritoneum in Health and Disease","volume":"1","author":"Solass W.","year":"2019","journal-title":"Pleura and Peritoneum"},{"issue":"6","key":"e_1_2_8_190_1","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1016\/j.jid.2016.11.045","article-title":"Human Skin Is the Largest Epithelial Surface for Interaction With Microbes","volume":"137","author":"Gallo R. L.","year":"2017","journal-title":"Journal of Investigative Dermatology"},{"issue":"6","key":"e_1_2_8_191_1","doi-asserted-by":"crossref","first-page":"1664","DOI":"10.3390\/pharmaceutics15061664","article-title":"Anatomical Targeting of Anticancer Drugs to Solid Tumors Using Specific Administration Routes: Review","volume":"15","author":"Saito A.","year":"2023","journal-title":"Pharmaceutics"},{"key":"e_1_2_8_192_1","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1007\/978-3-030-28891-4_19","volume-title":"Cancer Regional Therapy","author":"Beane J. D.","year":"2020"},{"issue":"1","key":"e_1_2_8_193_1","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1186\/s13045-023-01492-8","article-title":"Challenges and New Technologies in Adoptive Cell Therapy","volume":"16","author":"Zhang P.","year":"2023","journal-title":"Journal of Hematology & Oncology"},{"key":"e_1_2_8_194_1","doi-asserted-by":"publisher","DOI":"10.1002\/EXP.20210058"},{"key":"e_1_2_8_195_1","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.2147\/JPR.S158230","article-title":"Immune Function After Major Surgical Interventions: The Effect of Postoperative Pain Treatment","volume":"11","author":"Amodeo G.","year":"2018","journal-title":"Journal of Pain Research"},{"issue":"8","key":"e_1_2_8_196_1","doi-asserted-by":"crossref","first-page":"1787","DOI":"10.3390\/ijms18081787","article-title":"Dysfunctional Natural Killer Cells in the Aftermath of Cancer Surgery","volume":"18","author":"Angka L.","year":"2017","journal-title":"International Journal of Molecular Sciences"},{"issue":"1","key":"e_1_2_8_197_1","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1002\/ctm2.24","article-title":"Surgical Trauma\u2010Induced Immunosuppression in Cancer: Recent Advances and the Potential Therapies","volume":"10","author":"Tang F.","year":"2020","journal-title":"Clinical and Translational Medicine"},{"issue":"3","key":"e_1_2_8_198_1","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1016\/j.bbi.2009.02.010","article-title":"Immune Perturbations in Patients Along the Perioperative Period: Alterations in Cell Surface Markers and Leukocyte Subtypes before and After Surgery","volume":"24","author":"Bartal I.","year":"2010","journal-title":"Brain, Behavior, and Immunity"},{"issue":"5","key":"e_1_2_8_199_1","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1007\/s10151-014-1263-4","article-title":"Surgical Stress Response After Colorectal Resection: A Comparison of Robotic, Laparoscopic, and Open Surgery","volume":"19","author":"Shibata J.","year":"2015","journal-title":"Techniques in Coloproctology"},{"key":"e_1_2_8_200_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.807539"},{"issue":"9","key":"e_1_2_8_201_1","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1007\/s00595-010-4323-z","article-title":"Immunosuppression Following Surgical and Traumatic Injury","volume":"40","author":"Kimura F.","year":"2010","journal-title":"Surgery Today"},{"issue":"1","key":"e_1_2_8_202_1","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.surge.2010.07.011","article-title":"Surgery Induced Immunosuppression","volume":"9","author":"Hogan B. V.","year":"2011","journal-title":"The Surgeon"},{"issue":"4","key":"e_1_2_8_203_1","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1097\/TA.0b013e318265cf87","article-title":"The Immune Response to Surgery and Trauma","volume":"73","author":"Marik P. E.","year":"2012","journal-title":"Journal of Trauma and Acute Care Surgery"},{"issue":"6","key":"e_1_2_8_204_1","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1097\/MCC.0000000000000883","article-title":"Measuring the Human Immune Response to Surgery: Multiomics for the Prediction of Postoperative Outcomes","volume":"27","author":"Verdonk F.","year":"2021","journal-title":"Current Opinion in Critical Care"},{"issue":"6","key":"e_1_2_8_205_1","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1038\/s12276-022-00784-2","article-title":"Tumor Regionalization After Surgery: Roles of the Tumor Microenvironment and Neutrophil Extracellular Traps","volume":"54","author":"Kwak S. B.","year":"2022","journal-title":"Experimental & Molecular Medicine"},{"key":"e_1_2_8_206_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.02155"},{"key":"e_1_2_8_207_1","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1016\/j.semcancer.2022.01.006","article-title":"Surgery\u2010Mediated Tumor\u2010Promoting Effects on the Immune Microenvironment","volume":"86","author":"Cheng X.","year":"2022","journal-title":"Seminars in Cancer Biology"},{"issue":"9","key":"e_1_2_8_208_1","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1038\/s41568-020-0281-y","article-title":"Neutrophil Diversity and Plasticity in Tumour Progression and Therapy","volume":"20","author":"Jaillon S.","year":"2020","journal-title":"Nature Reviews Cancer"},{"issue":"1","key":"e_1_2_8_209_1","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1084\/jem.20181170","article-title":"Neutrophils Facilitate Ovarian Cancer Premetastatic Niche Formation in the Omentum","volume":"216","author":"Lee W.","year":"2019","journal-title":"Journal of Experimental Medicine"},{"key":"e_1_2_8_210_1","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.937565","article-title":"Neutrophil Extracellular Traps: New Players in Cancer Research","volume":"13","author":"Zhao J.","year":"2022","journal-title":"Frontiers in immunology"},{"key":"e_1_2_8_211_1","doi-asserted-by":"publisher","DOI":"10.3389\/fsurg.2022.888630"},{"issue":"17","key":"e_1_2_8_212_1","doi-asserted-by":"crossref","first-page":"2219","DOI":"10.15252\/embj.201490147","article-title":"The Wound Inflammatory Response Exacerbates Growth of Pre\u2010Neoplastic Cells and Progression to Cancer","volume":"34","author":"Antonio N.","year":"2015","journal-title":"The EMBO Journal"},{"issue":"12","key":"e_1_2_8_213_1","doi-asserted-by":"crossref","first-page":"3747","DOI":"10.1245\/s10434-018-6691-3","article-title":"Natural Killer Cell IFN\u03b3 Secretion Is Profoundly Suppressed Following Colorectal Cancer Surgery","volume":"25","author":"Angka L.","year":"2018","journal-title":"Annals of Surgical Oncology"},{"issue":"10","key":"e_1_2_8_214_1","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1038\/s41568-022-00491-0","article-title":"Natural Killer Cells in Antitumour Adoptive Cell Immunotherapy","volume":"22","author":"Laskowski T. J.","year":"2022","journal-title":"Nature Reviews Cancer"},{"issue":"78","key":"e_1_2_8_215_1","doi-asserted-by":"crossref","first-page":"34810","DOI":"10.18632\/oncotarget.26199","article-title":"Peritoneal Nk Cells Are Responsive to IL\u201015 and Percentages Are Correlated With Outcome in Advanced Ovarian Cancer Patients","volume":"9","author":"Hoogstad\u2010van Evert J. S.","year":"2018","journal-title":"Oncotarget"},{"key":"e_1_2_8_216_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.575597"},{"issue":"1","key":"e_1_2_8_217_1","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1186\/s13048-016-0282-3","article-title":"IL\u201012 Expressing Oncolytic Herpes Simplex Virus Promotes Anti\u2010Tumor Activity and Immunologic Control of Metastatic Ovarian Cancer in Mice","volume":"9","author":"Thomas E. D.","year":"2016","journal-title":"Journal of Ovarian Research"},{"issue":"1","key":"e_1_2_8_218_1","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1038\/s41467-017-01385-8","article-title":"Re\u2010Designing Interleukin\u201012 to Enhance Its Safety and Potential as An Anti\u2010Tumor Immunotherapeutic Agent","volume":"8","author":"Wang P.","year":"2017","journal-title":"Nature Communications"},{"issue":"1","key":"e_1_2_8_219_1","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-000710","article-title":"Oncolytic Vaccinia Virus Delivering Tethered IL\u201012 Enhances Antitumor Effects With Improved Safety","volume":"8","author":"Ge Y.","year":"2020","journal-title":"Journal for Immunotherapy of Cancer"},{"issue":"1","key":"e_1_2_8_220_1","article-title":"Mediation of Antitumor Activity by AZD4820 Oncolytic Vaccinia Virus Encoding Il\u201012","volume":"32","author":"Kurokawa C.","year":"2024","journal-title":"Molecular Therapy: Oncology"},{"issue":"1","key":"e_1_2_8_221_1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.7150\/ijms.21433","article-title":"Innate Immunity Recovers Earlier Than Acquired Immunity During Severe Postoperative Immunosuppression","volume":"15","author":"Lachmann G.","year":"2018","journal-title":"International Journal of Medical Sciences"},{"issue":"11","key":"e_1_2_8_222_1","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1007\/s00262-015-1740-2","article-title":"Surgical Trauma Induces Postoperative T\u2010Cell Dysfunction in Lung Cancer Patients Through the Programmed Death\u20101 Pathway","volume":"64","author":"Xu P.","year":"2015","journal-title":"Cancer Immunology, Immunotherapy"},{"issue":"8","key":"e_1_2_8_223_1","doi-asserted-by":"crossref","first-page":"1856","DOI":"10.1158\/1078-0432.CCR-15-1849","article-title":"Reversing T\u2010Cell Dysfunction and Exhaustion in Cancer","volume":"22","author":"Zarour H. M.","year":"2016","journal-title":"Clinical Cancer Research"},{"issue":"4","key":"e_1_2_8_224_1","first-page":"541","article-title":"Regulatory Mechanisms and Reversal of Cd8\u2009+\u2009T Cell Exhaustion: A Literature Review","volume":"12","author":"Zhu W.","year":"2023","journal-title":"Biology (Basel)"},{"issue":"1","key":"e_1_2_8_225_1","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1177\/1753425913516659","article-title":"Major Surgical Trauma Differentially Affects T\u2010Cells and APC","volume":"21","author":"Albertsmeier M.","year":"2015","journal-title":"Innate Immunity"},{"issue":"6","key":"e_1_2_8_226_1","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1007\/s00595-013-0517-5","article-title":"Regulatory T Cells in the Blood: A New Marker of Surgical Stress","volume":"43","author":"Saito Y.","year":"2013","journal-title":"Surgery Today"},{"issue":"2","key":"e_1_2_8_227_1","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1097\/CCO.0000000000000925","article-title":"Novel Strategies to Improve Efficacy of Treatment With Tumor\u2010Infiltrating Lymphocytes (Tils) for Patients With Solid Cancers","volume":"35","author":"Tas L.","year":"2023","journal-title":"Current Opinion in Oncology"},{"key":"e_1_2_8_228_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.1018962"},{"issue":"1","key":"e_1_2_8_229_1","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.pccm.2022.11.001","article-title":"Targeting Tumor Microenvironment for Non\u2010Small Cell Lung Cancer Immunotherapy","volume":"1","author":"Wang L.","year":"2023","journal-title":"Chinese Medical Journal Pulmonary and Critical Care Medicine"},{"issue":"5","key":"e_1_2_8_230_1","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1007\/s11912-023-01380-x","article-title":"Car\u2010T Therapies in Solid Tumors: Opportunities and Challenges","volume":"25","author":"Guzman G.","year":"2023","journal-title":"Current Oncology Reports"},{"key":"e_1_2_8_231_1","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1038\/s41573-021-00189-2","article-title":"Navigating Car\u2010T Cells Through the Solid\u2010Tumour Microenvironment","volume":"20","author":"Hou A. J.","year":"2021","journal-title":"Nature Reviews Drug Discovery"},{"issue":"1","key":"e_1_2_8_232_1","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1186\/s12935-023-02923-9","article-title":"CAR\u2010NKT Cell Therapy: A New Promising Paradigm of Cancer Immunotherapy","volume":"23","author":"Hadiloo K.","year":"2023","journal-title":"Cancer Cell International"},{"issue":"1","key":"e_1_2_8_233_1","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1038\/s41420-024-01815-9","article-title":"Breakthrough of Solid Tumor Treatment: CAR\u2010NK Immunotherapy","volume":"10","author":"Wang W.","year":"2024","journal-title":"Cell Death Discovery"},{"issue":"1","key":"e_1_2_8_234_1","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1186\/s13046-022-02327-z","article-title":"CAR Race to Cancer Immunotherapy: From Car T, CAR NK to Car Macrophage Therapy","volume":"41","author":"Pan K.","year":"2022","journal-title":"Journal of Experimental & Clinical Cancer Research"},{"issue":"1","key":"e_1_2_8_235_1","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1186\/s12943-023-01723-z","article-title":"CAR\u2010Cell Therapy in the Era of Solid Tumor Treatment: Current Challenges and Emerging Therapeutic Advances","volume":"22","author":"Maalej K. M.","year":"2023","journal-title":"Molecular Cancer"},{"key":"e_1_2_8_236_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1113882"},{"key":"e_1_2_8_237_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-021-00459-7"},{"issue":"2","key":"e_1_2_8_238_1","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1038\/s41577-021-00547-6","article-title":"Cytokine Release Syndrome and Associated Neurotoxicity in Cancer Immunotherapy","volume":"22","author":"Morris E. C.","year":"2022","journal-title":"Nature Reviews Immunology"},{"key":"e_1_2_8_239_1","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2019.00380"},{"issue":"1","key":"e_1_2_8_240_1","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1146\/annurev-pathol-012414-040438","article-title":"Protein Glycosylation in Cancer","volume":"10","author":"Stowell S. R.","year":"2015","journal-title":"Annual Review of Pathology: Mechanisms of Disease"},{"issue":"1","key":"e_1_2_8_241_1","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbcan.2020.188464","article-title":"Altered Glycosylation in Cancer: A Promising Target for Biomarkers and Therapeutics","volume":"1875","author":"Thomas D.","year":"2021","journal-title":"Biochimica et Biophysica Acta (BBA) \u2010 Reviews on Cancer"},{"issue":"8","key":"e_1_2_8_242_1","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1080\/14728222.2018.1498845","article-title":"MUC16 as a Novel Target for Cancer Therapy","volume":"22","author":"Aithal A.","year":"2018","journal-title":"Expert Opinion on Therapeutic Targets"},{"issue":"1","key":"e_1_2_8_243_1","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1007\/s10238-024-01365-5","article-title":"MUC16: Clinical Targets With Great Potential","volume":"24","author":"Zhang X. Y.","year":"2024","journal-title":"Clinical and Experimental Medicine"},{"issue":"5","key":"e_1_2_8_244_1","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1158\/1078-0432.CCR-21-1798","article-title":"Immunopet of Ovarian and Pancreatic Cancer With AR9.6, a Novel MUC16\u2010Targeted Therapeutic Antibody","volume":"28","author":"Sharma S. K.","year":"2022","journal-title":"Clinical Cancer Research"},{"issue":"3","key":"e_1_2_8_245_1","doi-asserted-by":"crossref","first-page":"110","DOI":"10.18632\/genesandcancer.104","article-title":"MUC16 Contributes to the Metastasis of Pancreatic Ductal Adenocarcinoma Through Focal Adhesion Mediated Signaling Mechanism","volume":"7","author":"Muniyan S.","year":"2016","journal-title":"Genes & Cancer"},{"issue":"9","key":"e_1_2_8_246_1","doi-asserted-by":"crossref","first-page":"2881","DOI":"10.1016\/j.ymthe.2022.07.006","article-title":"Targeting Glycans for Car Therapy: The Advent of Sweet CARs","volume":"30","author":"Raglow Z.","year":"2022","journal-title":"Molecular Therapy"},{"issue":"2","key":"e_1_2_8_247_1","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-001222","article-title":"Tumor\u2010Associated Carbohydrates and Immunomodulatory Lectins as Targets for Cancer Immunotherapy","volume":"8","author":"Rodrigues Mantuano N.","year":"2020","journal-title":"Journal for Immunotherapy of Cancer"},{"issue":"1","key":"e_1_2_8_248_1","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2022-005891","article-title":"Novel Banana Lectin CAR\u2010T Cells to Target Pancreatic Tumors and Tumor\u2010Associated Stroma","volume":"11","author":"McKenna M. K.","year":"2023","journal-title":"Journal for Immunotherapy of Cancer"},{"issue":"1","key":"e_1_2_8_249_1","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1186\/s40425-017-0222-9","article-title":"Safety, Tumor Trafficking and Immunogenicity of Chimeric Antigen Receptor (CAR)\u2010T Cells Specific for TAG\u201072 in Colorectal Cancer","volume":"5","author":"Hege K. M.","year":"2017","journal-title":"Journal for Immunotherapy of Cancer"},{"key":"e_1_2_8_250_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.02268"},{"issue":"1","key":"e_1_2_8_251_1","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-017-10940-8","article-title":"Armored CAR T Cells Enhance Antitumor Efficacy and Overcome the Tumor Microenvironment","volume":"7","author":"Yeku O. O.","year":"2017","journal-title":"Scientific Reports"},{"issue":"1","key":"e_1_2_8_252_1","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1186\/s12967-015-0460-x","article-title":"A Phase I Clinical Trial of Adoptive T Cell Therapy Using IL\u201012 Secreting MUC\u201016ecto Directed Chimeric Antigen Receptors for Recurrent Ovarian Cancer","volume":"13","author":"Koneru M.","year":"2015","journal-title":"Journal of Translational Medicine"},{"key":"e_1_2_8_253_1","doi-asserted-by":"publisher","DOI":"10.1186\/s40364-021-00264-1"},{"issue":"5","key":"e_1_2_8_254_1","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.3390\/cancers15051357","article-title":"Challenges of Anti\u2010Mesothelin CAR\u2010T\u2010Cell Therapy","volume":"15","author":"Zhai X.","year":"2023","journal-title":"Cancers"},{"issue":"1","key":"e_1_2_8_255_1","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1186\/s13287-022-02719-0","article-title":"Human Epidermal Growth Factor Receptor 2 (HER2)\u2010specific Chimeric Antigen Receptor (CAR) for Tumor Immunotherapy; Recent Progress","volume":"13","author":"Budi H. S.","year":"2022","journal-title":"Stem Cell Research & Therapy"},{"key":"e_1_2_8_256_1","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2021.111605","article-title":"Car\u2010Macrophage: A New Immunotherapy Candidate Against Solid Tumors","volume":"139","author":"Chen Y.","year":"2021","journal-title":"Biomedicine & Pharmacotherapy"},{"issue":"1","key":"e_1_2_8_257_1","doi-asserted-by":"crossref","DOI":"10.1038\/s41392-022-01198-2","article-title":"A PD\u2010L1\u2010targeting Chimeric Switch Receptor Enhances Efficacy of CAR\u2010T Cell for Pleural and Peritoneal Metastasis","volume":"7","author":"Ma Q.","year":"2022","journal-title":"Signal Transduction and Targeted Therapy"},{"issue":"2","key":"e_1_2_8_258_1","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.jcyt.2023.10.007","article-title":"Intraperitoneal Administration of Carcinoembryonic Antigen\u2010Directed Chimeric Antigen Receptor T Cells Is a Robust Delivery Route for Effective Treatment of Peritoneal Carcinomatosis From Colorectal Cancer in Pre\u2010Clinical Study","volume":"26","author":"Qian S.","year":"2024","journal-title":"Cytotherapy"},{"key":"e_1_2_8_259_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2024.42.16_suppl.3514"},{"key":"e_1_2_8_260_1","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2022.2147317"},{"key":"e_1_2_8_261_1","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1038\/s41416-023-02319-6","article-title":"Efficacy Evaluation of Chimeric Antigen Receptor\u2010Modified Human Peritoneal Macrophages in the Treatment of Gastric Cancer","volume":"129","author":"Dong X.","year":"2023","journal-title":"British Journal of Cancer"},{"key":"e_1_2_8_262_1","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1016\/j.jconrel.2023.07.021","article-title":"Dual Mrna Co\u2010Delivery for In Situ Generation of Phagocytosis\u2010Enhanced Car Macrophages Augments Hepatocellular Carcinoma Immunotherapy","volume":"360","author":"Yang Z.","year":"2023","journal-title":"Journal of Controlled Release"},{"issue":"1","key":"e_1_2_8_263_1","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1186\/s12929-023-00977-5","article-title":"Mrna\u2010Based Vaccines and Therapeutics: An In\u2010Depth Survey of Current and Upcoming Clinical Applications","volume":"30","author":"Wang Y. S.","year":"2023","journal-title":"Journal of Biomedical Science"},{"issue":"1","key":"e_1_2_8_264_1","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1038\/s41420-024-01815-9","article-title":"Breakthrough of Solid Tumor Treatment: CAR\u2010NK Immunotherapy","volume":"10","author":"Wang W.","year":"2024","journal-title":"Cell Death Discovery"},{"issue":"4","key":"e_1_2_8_265_1","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1038\/s41423-024-01145-x","article-title":"Development of Nk Cell\u2010Based Cancer Immunotherapies Through Receptor Engineering","volume":"21","author":"Page A.","year":"2024","journal-title":"Cellular & molecular immunology"},{"issue":"6","key":"e_1_2_8_266_1","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1016\/j.ymthe.2019.03.011","article-title":"Adoptive Transfer of NKG2D Car Mrna\u2010Engineered Natural Killer Cells in Colorectal Cancer Patients","volume":"27","author":"Xiao L.","year":"2019","journal-title":"Molecular Therapy"},{"issue":"16","key":"e_1_2_8_267_1","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2024.42.16_suppl.TPS5626","article-title":"Phase I\/II Study of TROP2 CAR Engineered IL15\u2010transduced Cord Blood\u2010Derived Nk Cells Delivered Intraperitoneally for the Management of Platinum Resistant Ovarian Cancer, Mesonephric\u2010Like Adenocarcinoma, and Pancreatic Cancer","volume":"42","author":"Knisely A.","year":"2024","journal-title":"Journal of Clinical Oncology"},{"issue":"3","key":"e_1_2_8_268_1","first-page":"2823","article-title":"Development of C\u2010Met\u2010Specific Chimeric Antigen Receptor\u2010Engineered Natural Killer Cells With Cytotoxic Effects on Human Liver Cancer HepG2 Cells","volume":"20","author":"Liu B.","year":"2019","journal-title":"Molecular Medicine Reports"},{"key":"e_1_2_8_269_1","doi-asserted-by":"publisher","DOI":"10.1093\/jleuko\/qiae144"},{"issue":"1","key":"e_1_2_8_270_1","article-title":"Empowering Pancreatic Tumor Homing With Augmented Anti\u2010Tumor Potency of CXCR2\u2010tethered CAR\u2010NK Cells","volume":"32","author":"Yoon J. H.","year":"2024","journal-title":"Molecular Therapy: Oncology"},{"issue":"14","key":"e_1_2_8_271_1","doi-asserted-by":"crossref","first-page":"3850","DOI":"10.7150\/ijbs.64630","article-title":"Development of Mesothelin\u2010Specific Car NK\u201092 Cells for the Treatment of Gastric Cancer","volume":"17","author":"Cao B.","year":"2021","journal-title":"International Journal of Biological Sciences"},{"issue":"4","key":"e_1_2_8_272_1","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1053\/j.gastro.2021.12.281","article-title":"Off\u2010The\u2010Shelf Prostate Stem Cell Antigen\u2013Directed Chimeric Antigen Receptor Natural Killer Cell Therapy to Treat Pancreatic Cancer","volume":"162","author":"Teng K. Y.","year":"2022","journal-title":"Gastroenterology"},{"key":"e_1_2_8_273_1","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1016\/j.jconrel.2020.07.016","article-title":"Rationally Designed Redirection of Natural Killer Cells Anchoring a Cytotoxic Ligand for Pancreatic Cancer Treatment","volume":"326","author":"Lee Y. E.","year":"2020","journal-title":"Journal of Controlled Release"},{"key":"e_1_2_8_274_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1230893"},{"key":"e_1_2_8_275_1","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.adc8738"},{"key":"e_1_2_8_276_1","doi-asserted-by":"crossref","DOI":"10.1177\/15330338221150322","article-title":"Promising Clinical Applications of Hydrogels Associated With Precise Cancer Treatment: A Review","volume":"22","author":"Wang Q.","year":"2023","journal-title":"Technology in Cancer Research & Treatment"},{"key":"e_1_2_8_277_1","doi-asserted-by":"publisher","DOI":"10.3389\/fbioe.2023.1140436"},{"key":"e_1_2_8_278_1","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202300517"},{"key":"e_1_2_8_279_1","doi-asserted-by":"publisher","DOI":"10.34133\/bmef.0016"},{"issue":"3","key":"e_1_2_8_280_1","doi-asserted-by":"crossref","first-page":"1746","DOI":"10.1021\/acs.chemrev.0c00779","article-title":"The Use of Alternative Strategies for Enhanced Nanoparticle Delivery to Solid Tumors","volume":"121","author":"Izci M.","year":"2021","journal-title":"Chemical Reviews"},{"issue":"8","key":"e_1_2_8_281_1","doi-asserted-by":"crossref","first-page":"10371","DOI":"10.1021\/acsami.2c19769","article-title":"Engineered Apoptosis\u2010Bioinspired Nanoparticles Initiate Immune Cascade for Cancer Immunotherapy of Malignant Ascites","volume":"15","author":"Huang A.","year":"2023","journal-title":"ACS Applied Materials & Interfaces"},{"issue":"7","key":"e_1_2_8_282_1","doi-asserted-by":"crossref","first-page":"727","DOI":"10.3390\/vaccines12070727","article-title":"An Overview of Nanoparticle\u2010Based Delivery Platforms for Mrna Vaccines for Treating Cancer","volume":"12","author":"Lin Y.","year":"2024","journal-title":"Vaccines"},{"issue":"11","key":"e_1_2_8_283_1","doi-asserted-by":"crossref","first-page":"1888","DOI":"10.3390\/pharmaceutics13111888","article-title":"Combination of Nanomaterials in Cell\u2010Based Drug Delivery Systems for Cancer Treatment","volume":"13","author":"Tang L.","year":"2021","journal-title":"Pharmaceutics"},{"key":"e_1_2_8_284_1","doi-asserted-by":"publisher","DOI":"10.1002\/EXP.20210106"},{"issue":"1","key":"e_1_2_8_285_1","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1186\/s11671-021-03588-x","article-title":"Cells\u2010Based Drug Delivery for Cancer Applications","volume":"16","author":"Du Y.","year":"2021","journal-title":"Nanoscale Research Letters"},{"key":"e_1_2_8_286_1","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.2147\/JPR.S158230","article-title":"Immune Function After Major Surgical Interventions: The Effect of Postoperative Pain Treatment","volume":"11","author":"Amodeo G.","year":"2018","journal-title":"Journal of Pain Research"},{"issue":"3","key":"e_1_2_8_287_1","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1007\/BF02887817","article-title":"Effects of Surgical Trauma on Interleukin 2 Production and Interleukin 2 Receptor Expression","volume":"12","author":"Hua L.","year":"1992","journal-title":"Journal of Tongji Medical University"},{"issue":"1","key":"e_1_2_8_288_1","first-page":"45","article-title":"Impaired Production of Interleukin\u20102 After Surgery","volume":"59","author":"Akiyoshi T.","year":"1985","journal-title":"Clinical and Experimental Immunology"},{"key":"e_1_2_8_289_1","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2023.104539","article-title":"A Systematic Review of Interleukin\u20102\u2010Based Immunotherapies in Clinical Trials for Cancer and Autoimmune Diseases","volume":"90","author":"Raeber M. E.","year":"2023","journal-title":"EBioMedicine"},{"issue":"3","key":"e_1_2_8_290_1","first-page":"1951","article-title":"Free\u2010From\u2010Progression Period and Overall Short Preoperative Immunotherapy With IL\u20102 Increases the Survival of Pancreatic Cancer Patients Treated With Macroscopically Radical Surgery","volume":"28","author":"Caprotti R.","year":"2008","journal-title":"Anticancer Research"},{"issue":"9","key":"e_1_2_8_291_1","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1038\/sj.bjc.6603391","article-title":"Perioperative Immunomodulation With interleukin\u20102 in Patients With Renal Cell Carcinoma: Results of a Controlled Phase II Trial","volume":"95","author":"Klatte T.","year":"2006","journal-title":"British Journal of Cancer"},{"issue":"1","key":"e_1_2_8_292_1","first-page":"599","article-title":"Pre\u2010Operative Immunoprophylaxis With interleukin\u20102 May Improve Prognosis in Radical Surgery for Colorectal Cancer Stage B\u2010C","volume":"26","author":"Brivio F.","year":"2006","journal-title":"Anticancer Research"},{"issue":"12","key":"e_1_2_8_293_1","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.1158\/2159-8290.CD-16-0577","article-title":"Improved Efficacy of Neoadjuvant Compared to Adjuvant Immunotherapy to Eradicate Metastatic Disease","volume":"6","author":"Liu J.","year":"2016","journal-title":"Cancer Discovery"},{"issue":"10","key":"e_1_2_8_294_1","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1038\/s41577-022-00680-w","article-title":"Engineering IL\u20102 for Immunotherapy of Autoimmunity and Cancer","volume":"22","author":"Hernandez R.","year":"2022","journal-title":"Nature Reviews Immunology"},{"issue":"10","key":"e_1_2_8_295_1","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1038\/s41577-018-0046-y","article-title":"Biology and Regulation of IL\u20102: From Molecular Mechanisms to Human Therapy","volume":"18","author":"Spolski R.","year":"2018","journal-title":"Nature Reviews Immunology"},{"issue":"9","key":"e_1_2_8_296_1","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.3390\/cells12091316","article-title":"Rethinking Oncologic Treatment Strategies With Interleukin\u20102","volume":"12","author":"Ko B.","year":"2023","journal-title":"Cells"},{"issue":"2","key":"e_1_2_8_297_1","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1007\/s00262-009-0750-3","article-title":"A Phase Ii Trial of Intraperitoneal interleukin\u20102 in Patients With Platinum\u2010Resistant or Platinum\u2010Refractory Ovarian Cancer","volume":"59","author":"Vlad A. M.","year":"2010","journal-title":"Cancer Immunology, Immunotherapy"},{"issue":"12","key":"e_1_2_8_298_1","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1001\/archsurg.1986.01400120019002","article-title":"Intraperitoneal Administration of Interleukin\u20102 in Patients With Cancer","volume":"121","author":"Lotze M. T.","year":"1986","journal-title":"Archives of Surgery"},{"key":"e_1_2_8_299_1","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.abm1032"},{"issue":"23","key":"e_1_2_8_300_1","doi-asserted-by":"crossref","first-page":"5927","DOI":"10.1158\/1078-0432.CCR-14-0804","article-title":"Phase II Clinical Trial of Amatuximab, a Chimeric Antimesothelin Antibody With Pemetrexed and Cisplatin in Advanced Unresectable Pleural Mesothelioma","volume":"20","author":"Hassan R.","year":"2014","journal-title":"Clinical Cancer Research"},{"issue":"4","key":"e_1_2_8_301_1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1136\/ijgc-2022-003927","article-title":"Safety and Activity of Anti\u2010Mesothelin Antibody\u2013Drug Conjugate Anetumab Ravtansine in Combination With Pegylated\u2010Liposomal Doxorubicin in Platinum\u2010Resistant Ovarian Cancer: Multicenter, Phase Ib Dose Escalation and Expansion Study","volume":"33","author":"Santin A. D.","year":"2023","journal-title":"International Journal of Gynecological Cancer"},{"issue":"4","key":"e_1_2_8_302_1","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1016\/S1470-2045(22)00061-4","article-title":"Anetumab Ravtansine Versus Vinorelbine in Patients With Relapsed, Mesothelin\u2010Positive Malignant Pleural Mesothelioma (Arcs\u2010M): a Randomised, Open\u2010Label Phase 2 Trial","volume":"23","author":"Kindler H. L.","year":"2022","journal-title":"The Lancet Oncology"},{"issue":"11","key":"e_1_2_8_303_1","doi-asserted-by":"crossref","first-page":"1548","DOI":"10.1038\/bjc.2015.380","article-title":"Phase I Trial of EpCAM\u2010Targeting Immunotoxin MOC31PE, Alone and in Combination With Cyclosporin","volume":"113","author":"Andersson Y.","year":"2015","journal-title":"British Journal of Cancer"},{"key":"e_1_2_8_304_1","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2024.1394878","article-title":"Direct Antitumor Activity of Bevacizumab: An Overlooked Mechanism?","volume":"15","author":"Wang Z.","year":"2024","journal-title":"Frontiers in Pharmacology"}],"container-title":["Journal of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/jso.70075","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,7]],"date-time":"2025-10-07T09:41:56Z","timestamp":1759830116000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/jso.70075"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,17]]},"references-count":303,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["10.1002\/jso.70075"],"URL":"https:\/\/doi.org\/10.1002\/jso.70075","archive":["Portico"],"relation":{},"ISSN":["0022-4790","1096-9098"],"issn-type":[{"type":"print","value":"0022-4790"},{"type":"electronic","value":"1096-9098"}],"subject":[],"published":{"date-parts":[[2025,9,17]]},"assertion":[{"value":"2024-09-03","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-07-30","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-09-17","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}